BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites
June 24, 2021, 3:06 pm
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers,
